Quantcast

Latest Factor VIII Stories

2011-02-16 07:00:00

KING OF PRUSSIA, Pa. and MONTREAL, Feb. 16, 2011 /PRNewswire/ -- As a means of aiding the World Federation of Hemophilia's (WFH) progress in improving the diagnosis and treatment of hemophilia in developing countries through its Global Alliance for Progress (GAP) program, CSL Behring has committed to donating more factor VIII concentrate (FVIII) to WFH. The donated product will be used in South America, Thailand, the Philippines, parts of eastern Europe, parts of the Middle East, and in...

2011-02-03 01:30:00

GENEVA, Feb. 3, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with hemophilia B. Results of the Phase 1 portion of an ongoing IB1001 clinical study demonstrated non-inferiority of IB1001 in achieving overall levels of replacement factor compared to BeneFIX®, the only approved recombinant...

2011-02-02 06:30:00

NES-ZIONA, Israel, Feb. 2, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX (Factor IX-CTP) in Factor IX-depleted hemophilic mice. The study was designed to measure the potential increase in clotting activity and duration of therapeutic effect of PROLOR's long-acting CTP-modified Factor IX when compared with commercially available recombinant...

2011-01-25 00:02:23

Octapharma has been committed to innovative patient care programs since inception and industry partnerships are central to the biopharmaceutical company's mission. As the most common inherited bleeding disorder in humans, von Willebrand Disease (VWD) affects one to two percent of the general population or approximately 3 million people in the United States. The severity of VWD is highly variable, from severe cases in which the tendency for excessive bleeding is obvious and treatment...

2010-12-08 09:30:00

HOBOKEN, N.J., Dec. 8, 2010 /PRNewswire/ -- Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease (VWD) and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation (NHF) Annual Meeting. According to the National Institutes of Health VWD is the most common inherited bleeding disorder and occurs in about 1 out of...

2010-12-01 07:30:00

KING OF PRUSSIA, Pa., Dec. 1, 2010 /PRNewswire/ -- CSL Behring announced today the availability of the next generation HeliTrax® System as part of a specially designed software platform for Apple's iPhone®, iPod touch®, or iPad(TM) devices. This enhanced system is designed to improve therapy management for people with hemophilia A who use CSL Behring's recombinant factor VIII (rFVIII). The new HeliTrax software is designed with an...

2010-11-08 09:30:00

HOBOKEN, N.J., Nov. 8, 2010 /PRNewswire/ -- Octapharma USA is proud to support educational initiatives for von Willebrand Disease (VWD), the most common inherited bleeding disorder, at the 62nd Annual Meeting of the National Hemophilia Foundation (NHF) scheduled for Nov. 11-13 in New Orleans. In addition to supporting several educational symposia discussing VWD, Octapharma will also provide poster presentations that will assist in increasing awareness of current research for the treatment...

2010-11-05 06:30:00

LAGUNA NIGUEL, Calif., Nov. 5, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the Company was awarded two grants, totaling $488,958, under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP). The grants are being provided under section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Care Act of 2010. The grants will be used to advance the clinical development of Inspiration's lead product...

2010-11-03 06:30:00

LAGUNA NIGUEL, Calif., Nov. 3, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the appointment of Karen A. Dawes to the Company's Board of Directors. Ms. Dawes brings to Inspiration over 20 years of healthcare marketing and commercialization experience, including the product launch of the only recombinant factor IX product currently on the market. Ms. Dawes will become the seventh member of Inspiration's Board of Directors. John Taylor, Co-Founder...

2010-11-01 10:00:00

HOBOKEN, N.J., Nov. 1, 2010 /PRNewswire/ -- Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study that is researching the use of the first recombinant Factor VIII (rFVIII) derived from a human cell line (Human-cl rhFVIII). Researchers are investigating Human-cl rhFVIII, to assess pharmacokinetics, efficacy, safety and...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.